A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin.
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2014
At a glance
- Drugs Telavancin (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Skin and soft tissue infections
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 01 Apr 2011 Actual end date (1 Feb 2011) added as reported by ClinicalTrials.gov.
- 01 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2010 Actual initiation date (Dec 2010) added as reported by ClinicalTrials.gov.